LANPL Inhibitors
Chemical inhibitors of LANPL can function by interfering with various cellular signaling pathways and processes that affect the activity state of the protein. Staurosporine operates as a potent kinase inhibitor, which can prevent the phosphorylation of LANPL, leading to its functional inhibition by maintaining it in an unphosphorylated state that is potentially inactive. Similarly, Okadaic Acid, by exclusively inhibiting protein phosphatases such as PP1 and PP2A, could effectively keep LANPL in a phosphorylated state, thereby inhibiting its activity if dephosphorylation is essential for LANPL function. The inhibition of apoptosis by Z-VAD-FMK results in the reduction of LANPL's involvement in apoptotic cell processing, thereby inhibiting its function within the cell, as the demand for its activity is reduced. MG-132, by disrupting the proteasome pathway, leads to the buildup of polyubiquitinated proteins, including LANPL, preventing its normal turnover and inhibiting its function due to the accumulation of ubiquitinated LANPL.
LY294002 and Wortmannin, both PI3K inhibitors, can prevent the activation of PI3K-dependent pathways, which can regulate LANPL function. This can lead to a reduction in the phosphorylation of downstream targets necessary for LANPL's activity, effectively inhibiting it. PD98059 and SB203580, which inhibit the MEK/ERK and p38 MAP kinase pathways respectively, can impede the signaling required for LANPL's functional role in cell growth, survival, and inflammatory response, leading to its inhibition. SP600125, as a JNK inhibitor, can disrupt pathways that regulate apoptosis and other cellular processes with which LANPL is associated, inhibiting its activity. Lactacystin, like MG-132, specifically targets the proteasome and can lead to an accumulation of LANPL, inhibiting its function by preventing its degradation. Lastly, Cyclosporin A and FK506 (Tacrolimus) both act on the calcineurin pathway. They inhibit calcineurin, which may prevent the dephosphorylation of LANPL, assuming that LANPL's activity is contingent on dephosphorylation. This inhibition would lead to LANPL remaining in a phosphorylated state, resulting in its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. LANPL is phosphorylatable, and its function can be influenced by its phosphorylation state. By inhibiting kinase activity, Staurosporine can prevent the phosphorylation of LANPL, leading to its functional inhibition. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a specific inhibitor of protein phosphatases PP1 and PP2A. LANPL may require dephosphorylation for its activity. By preventing dephosphorylation, Okadaic Acid can maintain LANPL in a phosphorylated and potentially inactive state. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can prevent apoptosis, a process in which LANPL is implicated. By inhibiting apoptosis, Z-VAD-FMK can indirectly reduce the demand for LANPL's role in apoptotic cell processing, functionally inhibiting its activity within the cell. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins. LANPL is known to be ubiquitinated, and its degradation via the proteasome is necessary for its function. Inhibition of the proteasome by MG-132 can thus stabilize LANPL, preventing its normal turnover and inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling can regulate various proteins including LANPL. Inhibition of PI3K by LY294002 can lead to a decrease in phosphorylation of downstream targets that are necessary for LANPL's function, thus indirectly inhibiting LANPL. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MEK/ERK pathway, which is involved in cell growth and survival. LANPL can be implicated in these cellular processes. Inhibition of the MEK/ERK pathway by PD98059 can lead to functional inhibition of LANPL due to the disruption of downstream signaling required for LANPL's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which plays a role in inflammatory responses and cell cycle regulation. LANPL is involved in these cellular processes. By inhibiting p38 MAP kinase activity, SB203580 can disrupt signaling pathways that are crucial for LANPL's function, resulting in its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is implicated in the regulation of apoptosis and other cellular processes. LANPL is also associated with these processes. By inhibiting JNK, SP600125 can disrupt the cellular pathways necessary for LANPL's function, leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another inhibitor of PI3K. Similar to LY294002, it prevents the activation of PI3K-dependent pathways that could regulate LANPL function. By doing so, Wortmannin can inhibit downstream signaling that may be required for the functional activity of LANPL. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. By inhibiting proteasomal degradation, it can lead to the accumulation of proteins including LANPL. This can result in the functional inhibition of LANPL as it might depend on proteasomal degradation for its regulation. | ||||||